Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Charcot-Marie-Tooth Disease, Type IA

Tundra lists 3 Charcot-Marie-Tooth Disease, Type IA clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT05902351

Natural History Study for Charcot Marie Tooth Disease

The goal of this Natural History Study for Charcot-Marie-Tooth is to acquire, record, and analyze patient-reported data and associated genetic reports, Electronic Health Records (EHRs) and clinical notes to identify the burden, diagnostic journey, and prevalence of disease that will aid scientists in their work toward finding a cure. Participants will be asked to complete a Natural History Survey.

Gender: All

Updated: 2026-09-17

1 state

Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth
Charcot-Marie-Tooth Disease, Type IA
+46
COMPLETED

NCT03397303

Quantification of Nerve Stiffness in Neuropathies

This project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . Stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. Patients will be compared with age-matched controls.

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-09-14

Chronic Inflammatory Demyelinating Polyneuropathy
Charcot-Marie-Tooth Disease, Type IA
Anti-MAG Neuropathy
COMPLETED

NCT03386266

Biomarkers and Validation of Selected Outcome Measures (CMTBiomarker)

CMT is a rare disease for which novel treatments are being developed. Evaluation of intervention efficacy is hampered by slow progression and lack of sensitive outcome measures. Primary goal of the project is to identify and validate RNA and protein derived biomarkers in blood of CMT patients for selected outcome measures over 2 years. The investigators expect to develop more responsive outcome measures and circulating biomarkers to improve assessment of intervention efficacy in forthcoming therapeutic trials.

Gender: All

Ages: 3 Years - 65 Years

Updated: 2026-05-06

1 state

Charcot-Marie-Tooth Disease, Type IA